ALNY vs. HUM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALNY and HUM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ALNY’s market capitalization stands at 43.28 billion USD, while HUM’s is 28.93 billion USD, indicating their market valuations are broadly comparable.
HUM carries a higher beta at 0.43, indicating it’s more sensitive to market moves, while ALNY (beta: 0.21) exhibits greater stability.
| Symbol | ALNY | HUM |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Humana Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Healthcare Plans |
| CEO | Yvonne L. Greenstreet | James A. Rechtin |
| Price | 331.91 USD | 239.68 USD |
| Market Cap | 43.28 billion USD | 28.93 billion USD |
| Beta | 0.21 | 0.43 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | December 31, 1981 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ALNY and HUM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALNY
-509.33%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
HUM
10.01%
Medical - Healthcare Plans Industry
- Max
- 13.94%
- Q3
- 13.62%
- Median
- 11.42%
- Q1
- 7.74%
- Min
- 6.98%
HUM’s Return on Equity of 10.01% is on par with the norm for the Medical - Healthcare Plans industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
ALNY
-2.79%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
HUM
5.69%
Medical - Healthcare Plans Industry
- Max
- 15.50%
- Q3
- 7.12%
- Median
- 5.48%
- Q1
- -3.47%
- Min
- -15.02%
HUM’s Return on Invested Capital of 5.69% is in line with the norm for the Medical - Healthcare Plans industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
ALNY
-11.49%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
HUM
1.42%
Medical - Healthcare Plans Industry
- Max
- 3.23%
- Q3
- 2.62%
- Median
- 1.70%
- Q1
- 1.27%
- Min
- 1.22%
HUM’s Net Profit Margin of 1.42% is aligned with the median group of its peers in the Medical - Healthcare Plans industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
ALNY
-4.91%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
HUM
2.78%
Medical - Healthcare Plans Industry
- Max
- 4.30%
- Q3
- 3.77%
- Median
- 2.61%
- Q1
- 1.60%
- Min
- -1.64%
HUM’s Operating Profit Margin of 2.78% is around the midpoint for the Medical - Healthcare Plans industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ALNY | HUM |
|---|---|---|
| Return on Equity (TTM) | -509.33% | 10.01% |
| Return on Assets (TTM) | -6.40% | 3.36% |
| Return on Invested Capital (TTM) | -2.79% | 5.69% |
| Net Profit Margin (TTM) | -11.49% | 1.42% |
| Operating Profit Margin (TTM) | -4.91% | 2.78% |
| Gross Profit Margin (TTM) | 86.01% | 100.00% |
Financial Strength
Current Ratio
ALNY
3.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ALNY’s Current Ratio of 3.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
HUM
1.91
Medical - Healthcare Plans Industry
- Max
- 1.91
- Q3
- 1.63
- Median
- 1.43
- Q1
- 0.85
- Min
- 0.78
HUM’s Current Ratio of 1.91 is in the upper quartile for the Medical - Healthcare Plans industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio
ALNY
11.28
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
With a Debt-to-Equity Ratio of 11.28, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
HUM
0.75
Medical - Healthcare Plans Industry
- Max
- 1.06
- Q3
- 0.86
- Median
- 0.75
- Q1
- 0.66
- Min
- 0.66
HUM’s Debt-to-Equity Ratio of 0.75 is typical for the Medical - Healthcare Plans industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ALNY
-0.79
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
HUM
5.05
Medical - Healthcare Plans Industry
- Max
- 6.23
- Q3
- 6.23
- Median
- 5.19
- Q1
- 4.64
- Min
- 3.18
HUM’s Interest Coverage Ratio of 5.05 is positioned comfortably within the norm for the Medical - Healthcare Plans industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ALNY | HUM |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 1.91 |
| Quick Ratio (TTM) | 2.98 | 1.91 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 0.75 |
| Debt-to-Asset Ratio (TTM) | 0.31 | 0.26 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.85 | 2.20 |
| Interest Coverage Ratio (TTM) | -0.79 | 5.05 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALNY and HUM. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
HUM
1.48%
Medical - Healthcare Plans Industry
- Max
- 3.88%
- Q3
- 1.78%
- Median
- 0.73%
- Q1
- 0.00%
- Min
- 0.00%
HUM’s Dividend Yield of 1.48% is consistent with its peers in the Medical - Healthcare Plans industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
HUM
25.15%
Medical - Healthcare Plans Industry
- Max
- 63.88%
- Q3
- 29.91%
- Median
- 12.57%
- Q1
- 0.00%
- Min
- 0.00%
HUM’s Dividend Payout Ratio of 25.15% is within the typical range for the Medical - Healthcare Plans industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | ALNY | HUM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.48% |
| Dividend Payout Ratio (TTM) | 0.00% | 25.15% |
Valuation
Price-to-Earnings Ratio
ALNY
-159.59
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ALNY has a negative P/E Ratio of -159.59. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
HUM
16.88
Medical - Healthcare Plans Industry
- Max
- 18.17
- Q3
- 17.32
- Median
- 15.48
- Q1
- 13.55
- Min
- 12.84
HUM’s P/E Ratio of 16.88 is within the middle range for the Medical - Healthcare Plans industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ALNY
-43.29
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ALNY has a negative Forward PEG Ratio of -43.29. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
HUM
0.80
Medical - Healthcare Plans Industry
- Max
- 1.41
- Q3
- 1.09
- Median
- 0.85
- Q1
- 0.79
- Min
- 0.60
HUM’s Forward PEG Ratio of 0.80 is within the middle range of its peers in the Medical - Healthcare Plans industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
ALNY
18.43
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ALNY’s P/S Ratio of 18.43 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
HUM
0.24
Medical - Healthcare Plans Industry
- Max
- 0.94
- Q3
- 0.64
- Median
- 0.43
- Q1
- 0.27
- Min
- 0.16
In the lower quartile for the Medical - Healthcare Plans industry, HUM’s P/S Ratio of 0.24 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio
ALNY
372.86
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
HUM
1.63
Medical - Healthcare Plans Industry
- Max
- 4.08
- Q3
- 3.83
- Median
- 2.63
- Q1
- 1.74
- Min
- 0.96
HUM’s P/B Ratio of 1.63 is in the lower quartile for the Medical - Healthcare Plans industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | ALNY | HUM |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -159.59 | 16.88 |
| Forward PEG Ratio (TTM) | -43.29 | 0.80 |
| Price-to-Sales Ratio (P/S, TTM) | 18.43 | 0.24 |
| Price-to-Book Ratio (P/B, TTM) | 372.86 | 1.63 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -574.08 | 12.15 |
| EV-to-EBITDA (TTM) | -285.32 | 9.22 |
| EV-to-Sales (TTM) | 18.55 | 0.32 |